LRCX Gains 8% on a $25B Buyback Plan: Is the Stock Worth Holding Now?

Lam Research shares rose 8.2% after the company announced a $25 billion share-repurchase authorization, following a 23.1% decline since its fiscal Q1 results. Q1 revenue increased 54% year over year to $8.22 billion and non-GAAP EPS rose 75% to $2.20, while Q2 revenue guidance is $8.6 billion, plus or minus $400 million, with management citing supply-chain constraints. Management expects 2026 systems revenue growth above 40% and wafer fabrication equipment spending in the mid-$150 billion range in 2026 and above $200 billion in 2027; the article recommends holding the stock.

Analysis

The buyback is a sentiment stabilizer, not a near-term demand catalyst: authorization does not guarantee execution, and repurchases made into a cyclical earnings peak can destroy value. The key issue is whether supply constraints defer shipments or signal a more persistent bottleneck; deferred shipments can support later quarters, but only if customer orders and utilization remain intact.

Near term (days to weeks), the 8% rebound risks front-running evidence that the weaker guide is recoverable. Over the next 1–3 months, watch shipment conversion, inventory and margin delivery—not just bookings—to establish whether constrained capacity is masking demand or limiting earnings. A miss against the company’s next revenue/margin outlook, or customer capex delays tied to AI infrastructure spending, would undermine the rebound. Management’s WFE and product-revenue projections are company forecasts, not independent confirmation.

Over 6–18 months, Lam’s memory exposure creates upside torque if HBM and NAND investment persists, but also greater sensitivity to memory-capex pauses. A broader equipment spending slowdown would likely pressure LRCX and peers, including AMAT and KLAC; continued complexity-driven investment could instead support tool demand and service revenue. The contrarian point: the lower historical multiple may reflect cyclicality and guide risk, not simply mispricing. Treat the authorization as optional support, not a valuation floor.

Key Decisions for Investors

• Do not chase the announcement-driven rally. Maintain a core LRCX position, but make adds conditional on the next report showing supply-constrained shipments converting to revenue without gross-margin slippage.
• For a 1–3 month risk check, track shipment timing, customer capex commentary and memory spending. Reduce exposure if guidance is cut or margins weaken; the thesis is falsified by evidence that demand—not supply—is the binding constraint.
• Treat the $25B authorization as a potential medium-term per-share tailwind only after verifying actual repurchase pace and net share-count reduction. If execution is limited while operating results soften, do not count the headline authorization as downside protection.